There are other tyrosine kinase inhibitors available for the treatment of CML and Ph+ ALL, such as Imatinib (Gleevec), Nilotinib (Tasigna), and Bosutinib (Bosulif). The choice of therapy depends on various factors including the patient's specific condition, previous treatments, and overall health status.
